glp-1 and addiction Anti-Obesity Rx Alcohol and Substance Use Disorders Frontiers | The therapeutic potential

The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal

His argument, put simply: We've spent two years talking about GLP-1 medicines as weight loss drugs

Speak to your health care provider before stopping GLP1-RAs to discuss when to stop and how to manage your condition

two minutes